Estrella Immunopharma (NASDAQ:ESLA) Cut to Sell at Wall Street Zen

Wall Street Zen cut shares of Estrella Immunopharma (NASDAQ:ESLA) from a hold rating to a sell rating in a report issued on Saturday.

ESLA has been the subject of several other research reports. D. Boral Capital reiterated a “buy” rating and set a $16.00 price target on shares of Estrella Immunopharma in a research note on Monday, November 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of Estrella Immunopharma in a research report on Friday, October 31st. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $16.00.

Estrella Immunopharma Price Performance

Shares of NASDAQ ESLA opened at $0.99 on Friday. The company has a 50 day simple moving average of $1.64 and a 200 day simple moving average of $1.42. Estrella Immunopharma has a 1 year low of $0.73 and a 1 year high of $3.15. The firm has a market cap of $37.54 million, a PE ratio of -2.92 and a beta of 0.55.

Estrella Immunopharma (NASDAQ:ESLA) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.06.

Estrella Immunopharma Company Profile

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.